Autosomal recessive optic atrophy, OPA7 type

Autosomal recessive optic atrophy, OPA7 type (also known as OPA7) is a rare inherited disorder of the optic nerve caused by biallelic mutations in the TMEM126A gene located on chromosome 11q14.1. This condition primarily affects the visual system, leading to progressive degeneration of the optic nerve fibers, which transmit visual information from the eye to the brain. OPA7 was first described in families of North African descent and is characterized by early-onset, progressive bilateral optic atrophy resulting in significant visual impairment. Patients with OPA7 typically present in early childhood with progressive loss of visual acuity affecting both eyes. Clinical features include reduced visual acuity, central visual field defects (central scotomas), color vision abnormalities (dyschromatopsia), and pallor of the optic disc observed on fundoscopic examination. The severity of vision loss can vary but often leads to significant visual disability. Unlike some other forms of hereditary optic atrophy, OPA7 follows an autosomal recessive inheritance pattern, meaning that both copies of the TMEM126A gene must carry pathogenic variants for the disease to manifest. The TMEM126A protein is believed to play a role in mitochondrial function, and its dysfunction leads to impaired energy metabolism in retinal ganglion cells, which are particularly vulnerable to mitochondrial defects. Currently, there is no specific curative treatment for OPA7. Management is primarily supportive and includes regular ophthalmologic monitoring, low-vision aids, and rehabilitative services to help patients maximize their remaining vision and maintain quality of life. Genetic counseling is recommended for affected families. Research into potential therapies, including gene therapy approaches targeting mitochondrial optic neuropathies, is ongoing but no approved treatments are yet available for this specific condition.

Common questions about Autosomal recessive optic atrophy, OPA7 type